Mark N. Sorial, PharmD, BCOP

Articles by Mark N. Sorial, PharmD, BCOP

Targeted Personalized Medicine Injection on Cancer Cell Model in Lab for Immunotherapy and CAR T-Cell Treatment Innovation | Image Credit: Oleksiy | stock.adobe.com

Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2

ByGrace Baek, PharmD, BCOP,Mark N. Sorial, PharmD, BCOP,Hannah Lee, BS,Matthew M. Lei, PharmD, BCOP

October 16th 2025

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.

B-cell lymphoma -- Image credit: Arif Biswas | stock.adobe.com

Bispecific T-Cell–Engaging Antibodies in B-Cell Lymphoma: Efficacy, Safety, and Practical Considerations

ByUvette Lou, PharmD, BCOP,Brenna Rowan, PharmD, BCOP,Abigail McLaren, PharmD, MS,E. Bridget Kim, PharmD, BCPS, BCOP,Mark N. Sorial, PharmD, BCOP,J. Erika Haydu, MD, PhD,Matthew M. Lei, PharmD, BCOP

August 16th 2024

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.

Latest Updated Articles

Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
Published: October 16th 2025 | Updated:

Mark N. Sorial, PharmD, BCOP

Articles by Mark N. Sorial, PharmD, BCOP

Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2

Bispecific T-Cell–Engaging Antibodies in B-Cell Lymphoma: Efficacy, Safety, and Practical Considerations

Latest Updated Articles

Trending on Pharmacy Times

Updated Hypertension Guidelines Are Here

Carefully Consider Ethical Implications of Artificial Intelligence Use in Pharmacy

FDA Approves Reformulated Ranitidine After 5-Year Absence

Application of the Age-Friendly 4M’s Movement Across Different Areas of Pharmacy

Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes